Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis

Journal of Young Pharmacists

Volumn 5, Issue 4, 2013, Pages 112-115

  Lakshmanan, Mageshwaran ^a   Xavier, Alphienes Stanley ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

ATP synthase inhibitor; Bedaquiline; MDR TB; Tuberculosis; XDR TB

Indexed keywords

EID: 84895109493     PISSN: 09751483     EISSN: 09751505     Source Type: Journal    
DOI: 10.1016/j.jyp.2013.12.002     Document Type: Review

References (30)

1. WHO Global Tuberculosis Report 2013 WHO [Internet]. [cited 2013 Nov 27]. Available from: http://www.who.int/tb/publications/global-report/en/
2. WHO Treatment of Tuberculosis: Guidelines for National Programmes [Internet]. WHO. [cited 2013 Nov 27]. Available from: http://www.who.int/tb/ publications/tb-treatmentguidelines/en/.
3. M. Spigelman, R. Woosley, and J. Gheuens New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 14 2010 663 664
4. M. Berney, and G.M. Cook Unique flexibility in energy metabolism allows mycobacteria to combat starvation and hypoxia PLoS One 5 2010 e8614
5. S.L. Tran, and G.M. Cook The F1Fo-ATP synthase of Mycobacterium smegmatis is essential for growth J Bacteriol 187 2005 5023 5028
6. Y. Hirono-Hara, H. Noji, and M. Nishiura et al. Pause and rotation of F(1)-ATPase during catalysis Proc Natl Acad Sci U S A 98 2001 13649 13654
7. R. Yasuda, T. Masaike, K. Adachi, H. Noji, H. Itoh, and K. Kinosita Jr. The ATP-waiting conformation of rotating F1-ATPase revealed by single-pair fluorescence resonance energy transfer Proc Natl Acad Sci U S A 100 2003 9314 9318
8. V.N. Kasho, and P.D. Boyer Vacuolar ATPases, like F1,F0-ATPases, show a strong dependence of the reaction velocity on the binding of more than one ATP per enzyme Proc Natl Acad Sci U S A 86 1989 8708 8711
9. A.C. Haagsma, I. Podasca, and A. Koul et al. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase PLoS One 6 2011 e23575
10. A.C. Haagsma, R. Abdillahi-Ibrahim, and M.J. Wagner et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue Antimicrob Agents Chemother 53 2009 1290 1292
11. Drugs@FDA: FDA Approved Drug Products [Internet]. [cited 2013 Nov 27]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.DrugDetails.
12. K.E. Dooley, J.-G. Park, and S. Swindells et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267 J Acquir Immune Defic Syndr 59 2012 455 462
13. K. Andries, P. Verhasselt, and J. Guillemont et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307 2005 223 227
14. M.-C. Rouan, N. Lounis, and T. Gevers et al. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis Antimicrob Agents Chemother 56 2012 1444 1451
15. N. Lounis, T. Gevers, J. Van Den Berg, and K. Andries Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model Antimicrob Agents Chemother 52 2008 3568 3572
16. M. Ibrahim, K. Andries, and N. Lounis et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis Antimicrob Agents Chemother 51 2007 1011 1015
17. K. Andries, T. Gevers, and N. Lounis Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis Antimicrob Agents Chemother 54 2010 4540 4544
18. N. Lounis, T. Gevers, J. Van den Berg, L. Vranckx, and K. Andries ATP synthase inhibition of Mycobacterium avium is not bactericidal Antimicrob Agents Chemother 53 2009 4927 4929
19. R.J. Basaraba, D.D. Dailey, and C.T. McFarland et al. Lymphadenitis as a major element of disease in the guinea pig model of tuberculosis Tuberc Edinb Scotl 86 2006 386 394
20. S. Shang, C.A. Shanley, and M.L. Caraway et al. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs Antimicrob Agents Chemother 55 2011 124 131
21. A.J. Lenaerts, D. Hoff, and S. Aly et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910 Antimicrob Agents Chemother 51 2007 3338 3345
22. R. Rustomjee, A.H. Diacon, and J. Allen et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis Antimicrob Agents Chemother 52 2008 2831 2835
23. A.H. Diacon, A. Pym, and M. Grobusch et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis N Engl J Med 360 2009 2397 2405
24. A.H. Diacon, P.R. Donald, and A. Pym et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance Antimicrob Agents Chemother 56 2012 3271 3276
25. Use of Bedaquiline (TMC-207) for treatment of MDR-TB [Internet] Int Union Against Tuberc Lung Dis 2012 [cited 2013 Nov 27]. Available from: http://uwclh.conference2web.com/content/2168
26. WHO Interim Guidance on the Use of Bedaquiline to Treat MDR-TB [Internet]. WHO. [cited 2013 Nov 27]. Available from: http://www.who.int/tb/ challenges/mdr/bedaquiline/en/index.html.
27. E. Huitric, P. Verhasselt, K. Andries, and S.E. Hoffner In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor Antimicrob Agents Chemother 51 2007 4202 4204
28. A. Koul, N. Dendouga, and K. Vergauwen et al. Diarylquinolines target subunit c of mycobacterial ATP synthase Nat Chem Biol 3 2007 323 324
29. M.R. De Jonge, L.H.M. Koymans, J.E.G. Guillemont, A. Koul, and K. Andries A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910 Proteins 67 2007 971 980
30. E. Segala, W. Sougakoff, A. Nevejans-Chauffour, V. Jarlier, and S. Petrella New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure Antimicrob Agents Chemother 56 2012 2326 2334